CuraTeQ

What CuraTeQ does

CuraTeQ Biologics Private Limited is a fully integrated biosimilar company founded in 2016 and headquartered in Hyderabad, India, operating as a wholly-owned subsidiary of Aurobindo Pharma, one of the world's largest pharmaceutical groups. The company develops, manufactures, and commercializes monoclonal antibody (mAb) biosimilars and recombinant biologics across oncology, immunology, osteology, haematology, endocrinology, and ophthalmology. As of 2025–2026, CuraTeQ has four commercially launched products — Bevqolva (bevacizumab), Dazublys (trastuzumab), Dyrupeg (pegfilgrastim), and Zefylti (filgrastim) — and a pipeline of 14+ biosimilar programs, with marketing authorizations secured from EMA, UK MHRA, Health Canada, and India CDSCO.

CuraTeQ's technology platform spans clone-to-commercial biosimilar development, including proprietary mammalian cell line development using CHO and HEK293 expression systems, orthogonal analytical characterization with ICH-compliant method validation, scalable upstream and downstream bioprocess development supported by Design-of-Experiment optimization and Process Analytical Technology, and end-to-end clinical development from Phase I PK/PD comparability studies through Phase III confirmatory efficacy trials. Manufacturing is anchored by a 10,000L (4 x 2,500L) GMP-certified bioreactor facility in Sangareddy, Hyderabad, which received EMA GMP certification following an April 2024 inspection covering mammalian and microbial drug substance manufacturing, prefilled syringe and vial filling, packaging, and QC testing. The company claims its therapies have reached 26 million+ patients globally across 50+ countries.

CuraTeQ operates a B2B distribution model selling biosimilar products to healthcare providers, hospitals, and oncology clinics. Revenue is generated through direct product sales (notably in India via CDSCO authorization and in Canada via Health Canada NOCs) and through out-licensing arrangements, exemplified by the March 2026 partnership with Germany's STADA Arzneimittel AG for EU commercialization of two EMA-approved biosimilars in France and Germany. The company leverages Aurobindo Pharma's global distribution network, regulatory affairs infrastructure, and procurement relationships for market access, and reports Phase 3 comparability success in 608-patient omalizumab and 446-patient denosumab studies. Specific pricing is not publicly disclosed and is negotiated with institutional buyers and government procurement channels.

Name

CuraTeQ

Legal name

CuraTeQ Biologics Private Limited

Website

https://curateqbio.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

501–1,000 employees

Short description

CuraTeQ Biologics is a Hyderabad-based, fully integrated biosimilar developer and wholly-owned subsidiary of Aurobindo Pharma, manufacturing monoclonal antibody biosimilars across oncology, immunology, haematology, osteology, endocrinology, and ophthalmology for healthcare providers, hospitals, and oncology clinics in 50+ countries.

Ownership category

akta.pro rank

Product category

Biosimilars / Biopharmaceutical Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)

akta.pro secondary industries

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF)

Keywords

• Biosimilar development
• Monoclonal antibody manufacturing
• GMP biologics production
• Mammalian cell bioprocessing
• Oncology biosimilars

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Biosimilar Product Sales: CuraTeQ generates revenue through sales of approved biosimilar products — Bevqolva (bevacizumab), Dyrupeg (pegylated filgrastim), Zefylti (filgrastim), and Dazublys (trastuzumab) — to healthcare providers and oncology clinics in regulated markets including India, UK, EU, and Canada. Revenue is driven by expanding commercial launches and market penetration across 50+ countries.
2. Out-licensing / Regional Partnerships: CuraTeQ out-licenses rights to approved biosimilars to regional commercialization partners. STADA Arzneimittel AG was granted rights to commercialize two EMA-approved biosimilars under new brand names in select EU countries including France and Germany, providing upfront and milestone-based licensing revenue.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

CuraTeQ Biologics develops, manufactures, and commercialises biosimilar monoclonal antibodies and recombinant biologics for oncology, immunology, haematology, endocrinology, and ophthalmology indications. The company operates a fully integrated clone-to-commercial platform covering mammalian cell line development (CHO and HEK293), scalable bioprocess development, GMP-certified manufacturing at 10,000L bioreactor scale, and clinical development through Phase III. Its launched portfolio includes Bevqolva (bevacizumab), Dazublys (trastuzumab), Dyrupeg (pegfilgrastim) and Zefylti (filgrastim), with a pipeline of 14+ biosimilar programs and approvals from EMA, MHRA, Health Canada and CDSCO.

Product overview

CuraTeQ Biologics is a fully integrated biosimilar company and wholly owned subsidiary of Aurobindo Pharma, headquartered in Hyderabad, India. The company develops, manufactures, and commercializes biosimilar products with a portfolio of 14+ biosimilar programs across oncology, haematology, immunology, endocrinology, and ophthalmology therapeutic areas. Their launched products include Bevqolva (bevacizumab), Dazublys (trastuzumab), Dyrupeg (pegylated filgrastim), and Zefylti (filgrastim). The company operates end-to-end capabilities from R&D through GMP manufacturing with 10,000L bioreactor capacity, serving 50+ countries through global regulatory approvals from EMA, MHRA, Health Canada, and CDSCO.

Differentiator

Problem solved

Functional benefit

Brands

• Bevqolva: Bevacizumab biosimilar for treatment of multiple cancers including colorectal and lung cancer
• Dyrupeg
• Zefylti
• Dazublys

Products and services

• Bevqolva (BP01) — bevacizumab biosimilar Bevacizumab biosimilar for treatment of metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or peritoneal cancer. Marketed to healthcare providers and oncology clinics in India, UK, EU, and Canada.
• Dazublys (BP02) — trastuzumab biosimilar Trastuzumab biosimilar for HER2-positive metastatic and early breast cancer and gastric cancer. Marketed in the EU with CHMP positive opinion and EC marketing authorisation.
• Dyrupeg (BP14) — pegfilgrastim biosimilar Pegylated filgrastim biosimilar for reduction of neutropenia duration and febrile neutropenia incidence in cancer patients treated with cytotoxic chemotherapy. Available as 6 mg prefilled syringe.
• Zefylti (BP13) — filgrastim biosimilar Filgrastim biosimilar for treatment of neutropenia and mobilisation of peripheral progenitor cells. Available in 30 MU/0.5 mL and 48 MU/0.5 mL prefilled syringe formulations.
• BP11 — omalizumab biosimilar Omalizumab biosimilar referencing Xolair for chronic spontaneous urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps. Phase 3 trial completed with 608 patients across Europe and India.
• BP16 — denosumab biosimilar Denosumab biosimilar referencing Prolia for treatment of postmenopausal osteoporosis and bone disorders. Phase 3 trial completed across 40 sites in five European countries.

Quantifiable outcome

• 26 million+ patients impacted globally through CuraTeQ's biosimilar therapies
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• STADA Arzneimittel AGcoreChannel Partner/ Reseller/ Distributor · 25 March 2026CuraTeQ Biologics partnered with German pharmaceutical company STADA Arzneimittel AG to market and distribute two EMA-approved biosimilars in select EU territories. STADA commercializes the products under new brand names in select EU countries including France and Germany. The partnership aims to expand CuraTeQ's market presence and boost revenue in the European region. This follows the broader industry trend of biosimilar companies leveraging established regional players for commercialization.
• BioFactura IncminorStrategic or Co-development Partner · 27 December 2025CuraTeQ Biologics mutually terminated its licensing agreement with US-based BioFactura Inc for BFI-751, a proposed biosimilar of ustekinumab (Stelara), effective December 27, 2025. The agreement, originally executed on July 7, 2023, was terminated following CuraTeQ's strategic portfolio prioritisation. The termination is not expected to have any material impact on Aurobindo's broader biosimilars strategy. This was a development and commercialisation support partnership that did not progress to commercial launch.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Zydus Cadila (Zydus Lifesciences): Indian pharmaceutical major with biosimilar programs including adalimumab and oncology biologics. Comparable in developing biosimilars targeting both Indian and global markets with integrated manufacturing.
• Dr. Reddy's Laboratories: Indian pharma major with a dedicated biologics arm developing and commercializing biosimilars including rituximab and other mAbs. Comparable in end-to-end biosimilar capabilities and emerging-markets distribution focus.
• Celltrion: Korean biopharmaceutical company with one of the broadest commercial biosimilar mAb portfolios globally (rituximab, trastuzumab, infliximab). Direct competitor in oncology biosimilars with established EMA/FDA approvals.
• Samsung Bioepis: Biosimilar-focused subsidiary of Samsung Group developing mAb biosimilars (etanercept, infliximab, adalimumab, ranibizumab) for global markets. Comparable in integrated biosimilar development and large-scale mammalian cell manufacturing.
• Alvotech: Pure-play biosimilar company developing mAb biosimilars (adalimumab, ustekinumab, aflibercept) targeting regulated markets with vertically integrated manufacturing. Closely comparable business model and regulatory strategy.
• Coherus Biosciences: US-based biosimilar commercializer with approved biosimilars including pegfilgrastim and trastuzumab, plus immunology assets. Comparable portfolio overlap, particularly in G-CSF and oncology biosimilars targeting regulated markets.
• Biocon Biologics: India-based, fully integrated biosimilar developer and manufacturer with a comparable portfolio of mAb biosimilars (trastuzumab, bevacizumab, filgrastim, pegfilgrastim). Most directly comparable peer given shared geography, scale of manufacturing, and overlapping therapeutic focus.
• Intas Pharmaceuticals (Accord BioPharma): India-headquartered generics player with a biosimilars division (Accord BioPharma) commercializing biosimilars including pegfilgrastim in regulated markets. Comparable vertically integrated biosimilar operations and India-based manufacturing.

Broad incumbents

• Amgen: Originator of key reference biologics (bevacizumab-equivalent franchise, denosumab, filgrastim) with growing biosimilars portfolio through Amjevita and others. Competes both as reference-product holder and biosimilar maker.
• Pfizer (biosimilars division): Large diversified pharma with a meaningful biosimilars portfolio including bevacizumab, trastuzumab, and rituximab biosimilars. Competes in same molecules but as part of broader portfolio, not a pure-play.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/curateq

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CuraTeQ